PDCD1 and neoplasm: PD-1 blockade therapy seems to counteract tumor-induced T cell dysfunctionality by interfering with PD-1/PD-L1 signals; it releases the negative regulation of T cells and promotes T cells which produced higher levels of IFN-γ to activate antitumor immune response (79–81).